All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

Ipamorelin CJC-1295 NO DAC

Ipamorelin + CJC-1295 (NO DAC) is a combination of two experimental peptides studied for their effects on growth hormone (GH) secretion. The combination targets two different regulatory pathways involved in the body’s natural control of growth hormone release.

Ipamorelin acts as a ghrelin receptor agonist, while CJC-1295 (NO DAC) is an analogue of growth hormone–releasing hormone (GHRH).

Because these peptides act through different physiological mechanisms, researchers have investigated whether their combined use can produce a synergistic stimulation of growth hormone secretion.

This combination is discussed mainly in experimental endocrine research and has not been approved as a pharmaceutical therapy.

How Ipamorelin CJC-1295 NO DAC works

The two peptides influence separate parts of the hormonal signaling system that regulates growth hormone release.

CJC-1295 (NO DAC):

  • stimulates GHRH receptors in the pituitary gland

  • triggers the physiological release of growth hormone

  • supports the natural pulsatile pattern of GH secretion

Ipamorelin:

  • activates the ghrelin receptor (GHS-R1a)

  • promotes additional growth hormone release from the pituitary

  • influences neuroendocrine pathways involved in GH regulation

When studied together, these peptides may:

  • produce greater GH release than either compound alone

  • mimic aspects of the body’s dual regulatory control of growth hormone (GHRH and ghrelin signaling)

  • increase circulating levels of insulin-like growth factor-1 (IGF-1) through activation of the GH axis

Because of these mechanisms, the combination has been explored in research related to endocrine physiology, metabolism, and growth hormone signaling.

Clinical trials and evidence

Research on combinations of GHRH analogues and growth hormone secretagogues has been conducted in experimental and early clinical settings. Studies have examined:

  • interactions between GHRH signaling and ghrelin receptor activation

  • the regulation of pulsatile growth hormone secretion

  • changes in circulating GH and IGF-1 levels

These studies have shown that stimulating both regulatory pathways simultaneously can produce stronger GH responses under controlled experimental conditions.

However, combinations such as Ipamorelin and CJC-1295 (NO DAC) have not been approved as pharmaceutical treatments, and most available data come from laboratory research and early clinical investigations.

Possible side effects of Ipamorelin CJC-1295 NO DAC:

Because this combination influences the growth hormone axis, potential side effects may be related to changes in GH and IGF-1 signaling. Possible effects may include:

  • headache

  • flushing

  • mild water retention

  • fatigue

  • injection site reactions

As with other investigational peptides affecting endocrine pathways, the long-term safety profile has not been fully established.

The combination of Ipamorelin and CJC-1295 (NO DAC) is considered an experimental peptide protocol studied primarily in endocrine research and is not approved as a prescription therapy by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

Ipamorelin + CJC-1295 NO DAC
Action: Growth hormone release stimulation | Category: GHRH + GHRP stack
Experimental dosage: 300–600 mcg | Frequency: once daily for 5 days, then 2 days off | Timing: evening | Cycle on: 12 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 4 weeks
Effectiveness: ■■■▢▢ | Safety: ■■■▢▢

Related peptides

Peptides from the same functional group:AOD9604, CJC-1295 NO DAC, CJC-1295 with DAC, GHRP-2, GHRP-6, Hexarelin

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged